Blue Note Therapeutics, Inc., today announced the closing of a Series A financing round of $26.25 million. Proceeds will allow the company to scale the organization and fund near-term clinical trials of its lead prescription digital therapeutic (PDT), which will potentially improve the treatment of cancer. The capital will also support the development of Blue Note’s pipeline assets. The Series A financing was led by JAZZ Venture Partners and joined by Summer VC. [Read more…] about Blue Note Therapeutics raises $26M to help treat cancer-related distress via cognitive behavioral stress management (CBSM)
Mindfulness in cancer treatment: time to stop and think (The Conversation):
“Breathe deeply and focus on the moment: mindfulness now appears everywhere as a technique to improve well-being, including in health care.
Mindfulness training is often suggested for cancer patients to reduce high levels of anxiety and distress associated with diagnosis, treatment and anticipation of possible disease recurrence. But two questions persist: does mindfulness work and, if so, for whom? [Read more…] about Growing research aims at helping cancer patients in distress access most-likely-to-help self-care options, from Mindfulness training to Web-based cognitive behavioral therapy (CBT)
“UCLA researchers have developed a program that could improve the day-to-day lives of women with breast cancer by addressing post-treatment cognitive difficulties, sometimes known as “chemo brain,” which can affect up to 35 percent of women after their treatments [Read more…] about Next: Tools to detect and treat “chemo brain” symptoms common in around 35% of breast cancer survivors
Good article today in the NYT on “chemo brain” — some typical short-term and long-term cognitive consequences of chemotherapy.
The Fog That Follows Chemotherapy (New York Times)
This quote is critical — for chemo brain and also for a variety of clinical conditions that present associated cognitive impairments: “Controlling for brain function before cancer treatment begins can help determine cause and effect. In one study, cancer patients took a battery of neuropsychological tests before starting chemotherapy, three weeks after completing treatment, and again one year later. Although a third of the patients had signs of cognitive impairment before therapy began, the number jumped to 61 percent after treatment, and half remained impaired a year later.”
As we have discussed before, we believe that inexpensive computerized cognitive assessments will start to become widely available in only a few years, to help set up individualized cognitive baselines and inform clinical diagnoses and treatments. For more, you can read Computerized Cognitive Assessments: opportunities and concerns